welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Restorative Proctectomy with Ileal Pouch-Anal Anastomosis in Obese PatientsPURPOSE : The aim of this study was to a...
-
Chemoprevention of Colorectal CancerColorectal cancer has become one of the ...
-
Ileal Pouch-Anal Anastomosis RegistryLittle is known about the factors that p...
-
Comparison of Proctocolectomy and Ileal Pouch-Anal Anastomosis to Colectomy and Ileorectal Anastomosis in Familial A...Prophylactic surgical options for famili...
-
Thomas Garofalo, MDThomas Garofalo, MD, FACS, is a Staff Su...
-
Texas Children’s HospitalTexas Children's Hospital, located in Ho...